ATE389017T1 - Verfahren zur selektiven hemmung des menschlichen n-myc-gens in n-myc exprimierenden tumoren durch antisense- und sense-peptidonukleinsäuren (pna) - Google Patents

Verfahren zur selektiven hemmung des menschlichen n-myc-gens in n-myc exprimierenden tumoren durch antisense- und sense-peptidonukleinsäuren (pna)

Info

Publication number
ATE389017T1
ATE389017T1 AT04730318T AT04730318T ATE389017T1 AT E389017 T1 ATE389017 T1 AT E389017T1 AT 04730318 T AT04730318 T AT 04730318T AT 04730318 T AT04730318 T AT 04730318T AT E389017 T1 ATE389017 T1 AT E389017T1
Authority
AT
Austria
Prior art keywords
myc
sense
antisense
pna
human
Prior art date
Application number
AT04730318T
Other languages
English (en)
Inventor
Roberto Tonelli
Raffaele Fronza
Andrea Pession
Stefano Sforza
Roberto Corradini
Rosangela Marchelli
Original Assignee
Univ Bologna Alma Mater
Univ Parma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Bologna Alma Mater, Univ Parma filed Critical Univ Bologna Alma Mater
Application granted granted Critical
Publication of ATE389017T1 publication Critical patent/ATE389017T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C12N2310/3181—Peptide nucleic acid, PNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
AT04730318T 2003-04-29 2004-04-29 Verfahren zur selektiven hemmung des menschlichen n-myc-gens in n-myc exprimierenden tumoren durch antisense- und sense-peptidonukleinsäuren (pna) ATE389017T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT000860A ITMI20030860A1 (it) 2003-04-29 2003-04-29 Metodo per l'inibizione selettiva del gene n-myc

Publications (1)

Publication Number Publication Date
ATE389017T1 true ATE389017T1 (de) 2008-03-15

Family

ID=33398059

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04730318T ATE389017T1 (de) 2003-04-29 2004-04-29 Verfahren zur selektiven hemmung des menschlichen n-myc-gens in n-myc exprimierenden tumoren durch antisense- und sense-peptidonukleinsäuren (pna)

Country Status (12)

Country Link
US (1) US7947657B2 (de)
EP (1) EP1618195B1 (de)
JP (1) JP4719670B2 (de)
AT (1) ATE389017T1 (de)
CA (1) CA2522890C (de)
DE (1) DE602004012404T2 (de)
DK (1) DK1618195T3 (de)
ES (1) ES2303636T3 (de)
IT (1) ITMI20030860A1 (de)
PL (1) PL1618195T3 (de)
PT (1) PT1618195E (de)
WO (1) WO2004096826A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060014289A1 (en) * 2004-04-20 2006-01-19 Nastech Pharmaceutical Company Inc. Methods and compositions for enhancing delivery of double-stranded RNA or a double-stranded hybrid nucleic acid to regulate gene expression in mammalian cells
US20060040882A1 (en) * 2004-05-04 2006-02-23 Lishan Chen Compostions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells
US20100136526A1 (en) 2005-12-26 2010-06-03 Takumi Era Therapeutic Agent for Neuroblastoma Targeting ARID3b
US20070281900A1 (en) * 2006-05-05 2007-12-06 Nastech Pharmaceutical Company Inc. COMPOSITIONS AND METHODS FOR LIPID AND POLYPEPTIDE BASED siRNA INTRACELLULAR DELIVERY
ITMI20120275A1 (it) * 2012-02-24 2013-08-25 Biogenera Societa A Responsabilita Limitata Oligonucleotidi per la modulazione dell'espressione genica e loro usi
EP3625344A1 (de) * 2017-05-15 2020-03-25 University of Florida Research Foundation, Inc. Hauptregulatoren von glioblastomstammzellen
US12016920B2 (en) * 2019-06-06 2024-06-25 Denka Company Limited Adjuvant based on peptide nucleic acid

Also Published As

Publication number Publication date
DE602004012404T2 (de) 2009-03-26
WO2004096826A2 (en) 2004-11-11
DK1618195T3 (da) 2008-07-07
JP2006525010A (ja) 2006-11-09
WO2004096826A3 (en) 2005-05-26
PT1618195E (pt) 2008-06-24
EP1618195A2 (de) 2006-01-25
EP1618195B1 (de) 2008-03-12
JP4719670B2 (ja) 2011-07-06
US7947657B2 (en) 2011-05-24
PL1618195T3 (pl) 2008-09-30
CA2522890A1 (en) 2004-11-11
ITMI20030860A1 (it) 2004-10-30
CA2522890C (en) 2013-07-02
DE602004012404D1 (de) 2008-04-24
ES2303636T3 (es) 2008-08-16
US20070020632A1 (en) 2007-01-25

Similar Documents

Publication Publication Date Title
ATE498685T1 (de) Antisense-oligonukleotide zur induktion von exon- skipping sowie verfahren zur verwendung davon
EP1750771A4 (de) Pankreasinsel-mikro-rna und verfahren zu ihrer unterdrückung
ATE397676T1 (de) Identifikation und verwendung von mirnas zur differenzierung myelogener leukämiezellen
DE60129799D1 (de) Verfahren zur steigerung des haarwuchses durch wnt polypeptid
ATE507838T1 (de) Verwendung von dipeptidylpeptidase iv und aminopeptidase-n inhibitoren zur behandlung von ischämie-induzierter neurodegeneration
WO2002006316A3 (en) Alpha-msh related compounds and methods of use
MX2008014100A (es) Compuestos y metodos para modular la expresion de pcsk9.
JP2010150280A5 (de)
ATE334657T1 (de) Hemmung der bcl-2 protein expression durch liposomale antisense-oligodeoxynukleotide
WO2005112981A3 (en) Compositions and methods for the stimulation or enhancement of bone formation and the self-renewal of cells
EP1513859A4 (de) Kinasesuppressor der ras-inaktivierung zur therapie von durch ras vermittelter tumorgenese
ATE389017T1 (de) Verfahren zur selektiven hemmung des menschlichen n-myc-gens in n-myc exprimierenden tumoren durch antisense- und sense-peptidonukleinsäuren (pna)
ATE514718T1 (de) Peptabody für krebsbehandlung
TN2011000459A1 (en) Vaccine compositions and methods for treatment of mucormycosis and other fungal diseases
ATE465261T1 (de) Integrin-gekoppelte kinase, ihre hemmstoffe und deren gebrauch für verfahren zur therapeutischen behandlung; gentherapie und bereitstellung von hemmstoffen, die als pseudosubstrate wirken
CY1108552T1 (el) Θεραπευτικη αντιμετωπιση της μη αλκοολικης στεατοηπατιτιδας (nash)
WO2005030225A3 (en) Method of inhibiting the expression of a multi-drug resistance genes and inhibiting the production of proteins resulting from the expression of such genes thereby enhancing the effectiveness of chemotherapeutic agents to treat cancers
WO2003016343A3 (en) USE OF αCP1, αCP2, AND HUR FOR MODULATING GENE EXPRESSION AND INDUCING ANGIOGENESIS
WO2005117974A3 (en) Cancer treatment method by inhibiting mage gene expression or function
EA200700346A1 (ru) Бактериофаг- и профаг-специфические протеины в генной терапии рака
WO2005060667A3 (en) Nucleic acid and amino acid sequences involved in pain
ATE396262T1 (de) Rna polymerase i transkriptionsfaktor tif-ia
TNSN06147A1 (en) Use of cathepsin k inhibitors for treating of severe bone loss diseases
ATE443257T1 (de) Verfahren zur identifizierung von tff2 regulierenden agentien
WO2004012654A3 (en) Oligonucleotides for treating proliferative disorders

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1618195

Country of ref document: EP